Molecular Formula | C24H26ClN5O3 |
Molar Mass | 467.95 |
Density | 1.293±0.06 g/cm3(Predicted) |
Solubility | DMSO: ≥ 30 mg/mL |
pKa | 9.47±0.20(Predicted) |
Storage Condition | -20℃ |
In vitro study | Treatment of cell lines from a variety of solid tumors with the combination of ACY-241 and paclitaxel can enhance the inhibition of cell proliferation. Compared with the single drug treatment, the combination treatment can also increase cell death, it also leads to abnormal Multipolar spindles and abnormal mitosis in dividing cells, which is associated with the formation of abnormal Multipolar spindles, induction of aneuploidy and increased cell death. In A2780 ovarian cancer cells, α-tubulin was highly acetylated and tubulin deacetylase HDAC6 was inhibited after 24 hours of 300 nM ACY-241 treatment. A low concentration of ACY-241 can selectively inhibit HDAC6, while a high concentration will result in inhibition of the class I HDAC isoenzyme. |
In vivo study | In vivo, ACY-241 had better safety than other non-selective pan-HDAC inhibition. In contrast, the side effects of ACY-241 are significantly reduced because of its low efficacy against class I HDACs, but still has anti-cancer potential. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.137 ml | 10.685 ml | 21.37 ml |
5 mM | 0.427 ml | 2.137 ml | 4.274 ml |
10 mM | 0.214 ml | 1.068 ml | 2.137 ml |
5 mM | 0.043 ml | 0.214 ml | 0.427 ml |